Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes

Atherosclerosis

Volumn 199, Issue 1, 2008, Pages 207-214

  Xiang, Anny H ^a   Hodis, Howard N ^a   Kawakubo, Miwa ^a   Peters, Ruth K ^a   Kjos, Siri L ^a,b   Marroquin, Aura ^a   Goico, Jose ^a   Ochoa, Cesar ^a   Liu, Chao ran ^a   Liu, Ci hua ^a   Buchanan, Thomas A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Gestational diabetes; Intima media thickness; Pioglitazone; Premenopausal

Indexed keywords

PIOGLITAZONE; TROGLITAZONE;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY DIABETES MELLITUS; PREMENOPAUSE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; CAROTID ARTERY DISEASES; CHROMANS; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PLACEBOS; PREGNANCY; PREMENOPAUSE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 45249120586     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.10.016     Document Type: Article

References (37)

1. Suzuki M., Takamisawa I., Yoshimasa Y., and Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Diabetes Res Clin Pract 76 1 (2007) 12-17
2. Esposito K., Ciotola M., Carleo D., et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 5 (2006) 1071-1076
3. Kruszynska Y.T., Yu J.G., Olefsky J.M., and Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49 4 (2000) 633-639
4. Hsueh W.A., and Law R.E. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21 (2001) 1891-1895
5. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
6. Hanefeld M., Marx N., Pfützner A., et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 49 3 (2007) 290-297
7. Dormandy J.A., Charbonnel B., Eclkand D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
8. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infaction and death from cardiovascular causes. N Engl J Med 356 24 (2007) 2457-2471
9. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3452-3456
10. Langefeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellius - results from a controlled randomized study. Circulation 111 (2005) 2525-2531
11. Nakamura T., Matsuda T., Kawagoe Y., et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 53 (2004) 1382-1386
12. Hodis H.N., Mack W.J., Zheng L., et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 29 7 (2006) 1545-1553
13. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 296 21 (2006) 2572-2581
14. Minamikawa J., Tanaka S., Yamauchi M., and Inoue D. Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83 (1998) 1818-2120
15. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (2004) 930-934
16. Xiang A.H., Peters R.K., Kjos S.L., et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 1986-1991
17. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2769-2803
18. Azen S.P., Berkowitz K., Kjos S., et al. TRIPOD: a randomized placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19 (1998) 217-231
19. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl. 1 (2004) S5-S10
20. Hodis H.N., Mack W.J., LaBree L., et al. Vitamin E supplementation in healthy individuals reduces LDL oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106 (2002) 1453-1459
21. Hodis H.N., Mack W.J., Lobo R.A., et al., for the Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the Prevention of Atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 135 (2001) 939-953
22. Selzer R.H., Mack W.J., Lee P.L., Kwong-Fu H., and Hodis H.N. Improved common carotid elasticity and intima-media thickness measurement from computer analysis of sequential ultrasound frames. Atherosclerosis 154 (2001) 185-193
23. Selzer R.H., Hodis H.N., Kwong-Fu H., et al. Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111 (1994) 1-11
24. Friedewald W.T., LevyRI, and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
25. Pacini G., and Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23 (1986) 113-122
26. Kjems L.L., Kirby B.M., Welsh E.M., et al. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50 (2001) 2001-2012
27. Vague P., and Moulin J.-P. The defective glucose sensitivity of the B-cell in noninsulin dependent diabetes: improvement after twenty hours of normoglycemia. Metabolism 31 (1982) 139-142
28. Bergman R.N., Phillips L.S., and Cobelli C. Physiologic evaluation of factors controlling glucose disposition in man. Measurement of insulin sensitivity and beta-cell sensitivity from the response to intravenous glucose. J Clin Invest 68 (1981) 1456-1467
29. Kahn S.E., Prigeon R.L., McCulloch D.K., et al. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42 (1993) 1663-1672
30. Howard G., Sharett A.R., Heiss G., et al., the ARIC Investigators. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke 24 (1993) 1297-1304
31. Wakino S., Kintscher U., Kim S., et al. Peroxisome proliferator-activated receptor g ligands inhibit retinoblastoma phosphorylation and GI S transition in vascular smooth muscle cells. J Biol Chem 275 (2000) 159-163
32. Shand B., Scott R., Connolly S., et al. Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 9 4 (2007) 540-547
33. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
34. Pajvani U.B., Hawkins M., Combs P., et al. Complex distribution, not absolute amount of adiponectin correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279 (2004) 12152-12162
35. Ghanim H., Garg R., Aljada A., et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86 (2001) 1306-1312
36. Sidhu J.S., Cowan D., and Kaski J.C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 42 (2003) 1757-1769
37. Lauenborg J., Mathiesen E., Hansen T., et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab 90 (2005) 4004-4010